Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 14/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9930542 | 0.85 | BRAF (0.53) | BRAFMAP2K1RAF1CYP2C9MAP2K4 | |
| SCHEMBL9930589 | 0.84 | BRAF (0.54) | BRAFMAP2K1RAF1CYP2C9MAP2K4 | |
| SCHEMBL1492043 | 0.80 | BRAF (0.43) | BRAFRAF1CYP2C9 | |
| SCHEMBL14574656 | 0.80 | BRAF (0.46) | BRAFMAP2K1RAF1CYP2C9MAP2K4 | |
| SCHEMBL9930275 | 0.79 | BRAF (0.48) | BRAFMAP2K1RAF1CYP2C9MAP2K4 | |
| SCHEMBL29561908 | 0.77 | BRAF (0.43) | BRAFCYP2C9 | |
| SCHEMBL22832046 | 0.77 | BRAF (0.43) | BRAFCYP2C9 | |
| SCHEMBL9930125 | 0.76 | BRAF (0.49) | BRAFMAP2K1RAF1CYP2C9MAP2K4 | |
| SCHEMBL913372 | 0.74 | BRAF (0.55) | BRAFMAP2K1RAF1CYP2C9MAP2K4 | |
| SCHEMBL912677 | 0.72 | BRAF (0.54) | BRAFMAP2K1RAF1CYP2C9MAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2013-01-17 | — | — | US | claimed |
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018033-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | BRAF 1/4885MAP2K1 36/4885RAF1 2/4885 |
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | BRAF 1/4885MAP2K1 36/4885RAF1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.